{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+prednisolone",
    "query": {
      "intervention": "Oral prednisolone"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 292,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+prednisolone&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T06:41:11.903Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05123040",
      "title": "Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute-graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib 10 MG Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "hCG",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-06-05",
      "completion_date": "2026-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123040"
    },
    {
      "nct_id": "NCT03661645",
      "title": "Post-operative Methylprednisolone Taper Course for Orthopedic Surgery",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Orthopedic Surgeries"
      ],
      "interventions": [
        {
          "name": "10 mg IV dexamethasone & 6 day oral methylprednisolone taper",
          "type": "DRUG"
        },
        {
          "name": "10 mg IV dexamethasone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 500,
      "start_date": "2018-09-07",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03661645"
    },
    {
      "nct_id": "NCT03752307",
      "title": "Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Isoxsuprine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2,
      "start_date": "2019-02-15",
      "completion_date": "2023-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03752307"
    },
    {
      "nct_id": "NCT00676832",
      "title": "Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "COLAL-PRED",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prometheus Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 190,
      "start_date": "2008-05",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2010-09-29",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 89,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676832"
    },
    {
      "nct_id": "NCT00282308",
      "title": "A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisone",
          "type": "DRUG"
        },
        {
          "name": "C. albicans",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus toxoid adsorbed booster vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23-valent pneumococcal polysaccharide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keyhole limpet hemocyanin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 103,
      "start_date": "2006-01-23",
      "completion_date": "2012-05-28",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00282308"
    },
    {
      "nct_id": "NCT00568633",
      "title": "Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myeloid",
        "Leukemia",
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Allogeneic HSCT",
          "type": "PROCEDURE"
        },
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine (CSP)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Total lymphoid irradiation (TLI)",
          "type": "RADIATION"
        },
        {
          "name": "Methylprednisolone sodium succinate",
          "type": "DRUG"
        },
        {
          "name": "Best standard care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 58,
      "start_date": "2007-08",
      "completion_date": "2015-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-09-24",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 5,
      "location_summary": "Hayward, California • Los Angeles, California • Sacramento, California + 2 more",
      "locations": [
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00568633"
    },
    {
      "nct_id": "NCT04206553",
      "title": "A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral corticosteroids (OCS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 106,
      "start_date": "2020-10-28",
      "completion_date": "2025-01-05",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04206553"
    },
    {
      "nct_id": "NCT03560466",
      "title": "Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dupilumab (SAR231893/REGN668)",
          "type": "DRUG"
        },
        {
          "name": "Asthma controller therapies (incl. prednisone/prednisolone)",
          "type": "DRUG"
        },
        {
          "name": "Asthma reliever therapies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 378,
      "start_date": "2018-06-21",
      "completion_date": "2025-04-01",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Rolling Hills Estates, California + 9 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03560466"
    },
    {
      "nct_id": "NCT03635957",
      "title": "Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Pegloticase",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Standard Gout Flare Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Infusion Reaction (IR) Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2018-09-26",
      "completion_date": "2020-10-26",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 6,
      "location_summary": "Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Bothell",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635957"
    },
    {
      "nct_id": "NCT04826237",
      "title": "Oral Statins and Protection From Hearing Loss",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sudden Sensorineural Hearing Loss"
      ],
      "interventions": [
        {
          "name": "Statin",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2023-02-09",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-09-14T06:41:11.903Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04826237"
    }
  ]
}